Can a diabetes drug rev up muscle power?

NCT ID NCT07771010

NEW Recruiting now Disease control Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial asks whether empagliflozin, metformin, or a combination of both can improve how muscles produce energy and respond to blood flow in people newly diagnosed with type 2 diabetes. About 54 men with type 2 diabetes will be randomly assigned to one of three groups: empagliflozin alone, metformin alone, or both drugs together. Over six months, researchers will use a non-invasive light-based technique to measure muscle oxygen recovery and blood vessel reactivity, alongside body composition and blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin and metformin, alone or in combination
What this could lead to: If empagliflozin improves muscle energy use, it could point to a better way to protect muscle function in people with type 2 diabetes.
What could go wrong: This is a small, early-stage study, and results may not apply to everyone. The drugs may not show a clear benefit on muscle health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES TYPE 2

Contacts and locations

Locations

UMC Ljubljana
RECRUITING

Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.